CA2867418C - Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections - Google Patents

Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections Download PDF

Info

Publication number
CA2867418C
CA2867418C CA2867418A CA2867418A CA2867418C CA 2867418 C CA2867418 C CA 2867418C CA 2867418 A CA2867418 A CA 2867418A CA 2867418 A CA2867418 A CA 2867418A CA 2867418 C CA2867418 C CA 2867418C
Authority
CA
Canada
Prior art keywords
bacteriophage
pharmaceutical composition
strains
seq
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2867418A
Other languages
English (en)
French (fr)
Other versions
CA2867418A1 (en
Inventor
Joao Joao Duarte Alves Mendes
Clara Isabel Rodrigues Leandro
Sofia Volker Corte-Real
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Original Assignee
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Tecnifar Industria Tecnica Farmaceutica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage Investigacao e Desenvolvimento em Biotecnologia SA, Tecnifar Industria Tecnica Farmaceutica SA filed Critical Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Publication of CA2867418A1 publication Critical patent/CA2867418A1/en
Application granted granted Critical
Publication of CA2867418C publication Critical patent/CA2867418C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320004—Surgical cutting instruments abrasive
    • A61B2017/320008—Scrapers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
CA2867418A 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections Active CA2867418C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612531P 2012-03-19 2012-03-19
US61/612,531 2012-03-19
PCT/PT2013/000016 WO2013141730A1 (en) 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
CA2867418A1 CA2867418A1 (en) 2013-09-26
CA2867418C true CA2867418C (en) 2020-03-10

Family

ID=48534472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867418A Active CA2867418C (en) 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Country Status (13)

Country Link
US (1) US9962419B2 (https=)
EP (1) EP2833899B1 (https=)
JP (1) JP6186427B2 (https=)
CN (1) CN104519893B (https=)
AU (1) AU2013235883B2 (https=)
BR (1) BR112014023321B1 (https=)
CA (1) CA2867418C (https=)
DK (1) DK2833899T3 (https=)
ES (1) ES2814024T3 (https=)
PT (1) PT2833899T (https=)
RU (1) RU2654596C2 (https=)
SG (1) SG11201405829WA (https=)
WO (1) WO2013141730A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
WO2016066722A2 (en) * 2014-10-28 2016-05-06 Ian Humphery-Smith Bacteriophage combinations for human or animal therapy
US10455983B2 (en) 2015-09-10 2019-10-29 Prince Castle LLC Modular food holding system
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
WO2017180862A1 (en) * 2016-04-13 2017-10-19 Northeast Ohio Medical University Gpnmb compositions for treatment of skin wounds
AU2017371484B2 (en) * 2016-12-05 2022-09-15 Technophage, Investigação e Desenvolvimento Em Biotecnologia SA Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
CN110719784A (zh) 2017-02-13 2020-01-21 阿玛塔制药公司 治疗性噬菌体组合物
EP3679579A1 (en) * 2017-09-05 2020-07-15 Adaptive Phage Therapeutics, Inc. Methods to determine the sensitivity profile of a bacterial strain to a therapeutic composition
US20190290736A1 (en) * 2017-10-19 2019-09-26 Fourward Technology, LLC Topical composition for improved healing of open wounds
CA3085314A1 (en) 2017-12-11 2019-06-20 Adaptive Phage Therapeutics, Inc. Phage dispensing system
CA3087338A1 (en) 2018-01-02 2019-07-11 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions for treating staphylococcus infection
CN109082414B (zh) * 2018-06-29 2020-11-13 浙江工业大学 一种金黄色葡萄球菌噬菌体及应用
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
CN109730235A (zh) * 2019-02-01 2019-05-10 珠海横琴普罗恩能医用食品有限公司 一种用于医用食品的防腐剂
US12576118B2 (en) 2019-05-21 2026-03-17 University of Pittsburgh—of the Commonwealth System of Higher Education Bacteriophages for the treatment of tuberculosis
US12594312B2 (en) 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection
CN111643724B (zh) * 2020-07-01 2022-01-28 南京大学 一种载有噬菌体和酸性成纤维细胞生长因子的水凝胶伤口敷料的制备方法及其应用
WO2022013318A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh New mosaic bacteriophages and uses thereof
WO2022013314A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh Bacteriophage cocktails and uses thereof
CN112251439B (zh) * 2020-10-26 2022-06-21 齐鲁师范学院 拟南芥高温诱导启动子pHTG1及其重组载体
CN112301001B (zh) * 2020-11-03 2022-10-14 华中农业大学 金黄色葡萄球菌噬菌体lsa2311及其应用
CN113201458B (zh) * 2020-12-21 2022-05-27 青岛诺安百特生物技术有限公司 一种提高噬菌体制剂稳定性的组合物及其应用
WO2022238947A1 (en) * 2021-05-12 2022-11-17 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
US20240277791A1 (en) * 2021-06-11 2024-08-22 Integrated Pharma Services, Llc Device and methods for acne therapeutics: antibacterial bacteriophages and engineered lysins
DE202022102100U1 (de) 2022-04-20 2022-04-27 Prabhakar Ramesh Bhandari Synergistische antibiotische pharmazeutische Zusammensetzung zur Behandlung von Staphylococcus aureus-Infektionen
WO2024115430A1 (en) * 2022-11-28 2024-06-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Acinetobacter baumannii phages
WO2025104708A1 (en) 2023-11-16 2025-05-22 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Method for determining the susceptibility of bacteria to bacteriophages

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699322B2 (en) 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6138401A (en) 1999-06-25 2000-10-31 Duncan; Franklin R. Fish hook remover
EP1504088B1 (en) * 2002-03-25 2007-08-15 University Of Warwick Bacteriophages useful for therapy and prophylaxis of bacterial infections
US20050095222A1 (en) 2003-10-29 2005-05-05 Taro Suzuki Allergen inhibitor, allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet
EP2462940A1 (en) 2004-11-02 2012-06-13 Chr. Hansen A/S Stabilized bacteriophage formulations
MX2007005279A (es) 2004-11-02 2008-03-11 Gangagen Life Sciences Inc Composiciones de bacteriofagos.
WO2006063176A2 (en) 2004-12-06 2006-06-15 The Government Of The Usa As Representedtd By The Secretary Of The Dept Of Health And Human Services Inhibition of biofilm formation using bacteriophage
EP1888088A4 (en) 2005-05-26 2012-07-04 Chr Hansen As BACTERIAL REGULATION IN ANIMAL CONTAINMENT SYSTEMS
AU2010211456B2 (en) 2009-02-06 2016-05-26 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Antibacterial phage, phage peptides and methods of use thereof
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
CA3048783C (en) * 2010-09-17 2022-05-24 Tecnifar-Industria Tecnica Farmaceutica, S.A. Antibacterial phage, phage peptides and methods of use thereof

Also Published As

Publication number Publication date
DK2833899T3 (da) 2020-09-28
BR112014023321A2 (pt) 2022-02-01
CA2867418A1 (en) 2013-09-26
US20150150919A1 (en) 2015-06-04
RU2014141941A (ru) 2016-05-20
RU2654596C2 (ru) 2018-05-21
CN104519893B (zh) 2020-02-07
AU2013235883A1 (en) 2014-10-02
ES2814024T3 (es) 2021-03-25
HK1207002A1 (en) 2016-01-22
EP2833899A1 (en) 2015-02-11
CN104519893A (zh) 2015-04-15
US9962419B2 (en) 2018-05-08
WO2013141730A1 (en) 2013-09-26
AU2013235883B2 (en) 2018-01-04
JP6186427B2 (ja) 2017-08-23
JP2015512384A (ja) 2015-04-27
SG11201405829WA (en) 2014-10-30
BR112014023321B1 (pt) 2022-06-14
EP2833899B1 (en) 2020-06-24
PT2833899T (pt) 2020-09-15

Similar Documents

Publication Publication Date Title
CA2867418C (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
JP6944399B2 (ja) プロバイオティクス細菌
Bowler et al. Wound microbiology and associated approaches to wound management
US9737579B2 (en) Antibacterial phage, phage peptides and methods of use thereof
EP2283130B1 (en) Dispersin B(TM), 5-fluorouracil, deoxyribonuclease I and proteinase K-based antibiofilm compositions and uses thereof
Aswathanarayan et al. Biofilm-associated infections in chronic wounds and their management
WO2004052308A2 (en) Topical anti-infective formulations
US12029766B2 (en) Pharmaceutical composition and methods for the prevention and/or treatment of Staphylococcus aureus using artificial bacterial colonization
CN104602700A (zh) 蜂蜜曲霉蛋白酶在用于去除细菌生物膜的用途
WO2020028561A1 (en) Bismuth-thiol compositions and methods for treating wounds
HK1207002B (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
US9925235B2 (en) Tilapia piscidins for use in enhancement of wound healing
CN1911442B (zh) 一种用于防治创面感染的溶葡萄球菌酶冻干粉剂
Durr Development of Antibacterial Hydrogels with Regenerative Benefits for Infected Wound Healing
WO2024160777A1 (en) Peptides for treatment of skin disease
TW201622741A (zh) 狗圍肛腺瘤之治療方法
Johnson Immune Modulatory and Antimicrobial Properties of Mesenchymal Stromal Cells Delivered Systemically
Gajakosh Prophylactic Antibiotic and Post Operative Surgical Wound Infection
Sreejith Effectiveness of Prophylactic Single Dose Antibiotic Versus Multiple Dose Post-Operative Antibiotics in Preventing Surgical Site Infections in Clean and Clean Contaminated Surgeries-A Comparitive Study

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180314

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250305

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250305

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309